Momenta Pharma Reports Data Presentation on M402 at ASCO Meeting

Momenta Pharmaceuticals, Inc. MNTA, a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of current data from its Phase 1 study of necuparanib in metastatic pancreatic cancer. The poster will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. Poster Presentation Details Abstract #4114: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase 1 Results Presentation Date/Time: Monday, June 1, 2015; 8:00 a.m –11:00 a.m. CDT Presenter: Eileen Mary O'Reilly, MD of David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center